Investor Landscape

Who's funding India healthtech and what it means for AarogyaDost

---

TL;DR

Investor Type	Key Players	Focus Areas
Top VCs	Accel, Peak XV, 3one4	PHR, longevity, platforms
Angels	Nikhil Kamath, Binny Bansal	Longevity, health innovation
Strategic	Tata, Reliance, Bajaj	Ecosystem plays
Global	Tencent, a16z, General Catalyst	Scale players

---

Venture Capital Firms

Tier 1 - Most Active in Healthtech

Accel India

Metric	Details
Portfolio	BioPeak, Eka Care (indirect), 100+ companies
Stage	Seed to Series B
Check size	$0.5M - $15M
Key Partner	Prashanth Prakash (Longevity India patron)
Thesis	Consumer tech, health innovation

Relevance to AarogyaDost: High - Prashanth Prakash personally invested in longevity. Strong signal for category.

Peak XV Partners (formerly Sequoia India)

Metric	Details
Portfolio	Practo ($228M total)
Stage	Seed to Growth
Check size	$1M - $100M+
Thesis	Category leaders, large markets

Relevance: Medium - Backed Practo, interested in healthcare scale plays.

3one4 Capital

Metric	Details
Portfolio	Eka Care
Stage	Seed to Series A
Check size	$0.5M - $5M
Thesis	India-first, consumer health

Relevance: High - Direct PHR investor, understands space.

Hummingbird Ventures

Metric	Details
Portfolio	Eka Care (Lead Series A)
Stage	Series A
Check size	$5M - $20M
Thesis	Deep tech, health innovation

Relevance: High - Led largest PHR round in India.

Tier 2 - Active in Adjacent Spaces

VC	Portfolio	Stage	Notes
Mirae Asset	Eka Care	Growth	Korean VC, healthcare focus
Verlinvest	Eka Care	Growth	Consumer brands, health
Aditya Birla Ventures	Eka Care	Corporate	Strategic health interest
Z47 (formerly NEA)	Practo	Growth	Global healthcare portfolio
AIA Group	Practo	Strategic	Insurance + healthcare

---

Angel Investors

High-Profile Health Angels

Nikhil Kamath (Zerodha)

Metric	Details
Investments	BioPeak, multiple health startups
Focus	Longevity, preventive health
Stage	Seed, early
Signal	Deeply interested in longevity personally

Why it matters: Co-founder of India's largest broker personally backing longevity. Strong market signal.

Binny Bansal (Flipkart co-founder)

Metric	Details
Investments	Eka Care
Focus	Consumer tech, health
Stage	Seed
Signal	Proven operator betting on PHR

Ranjan Pai (Claypond Capital / Manipal Group)

Metric	Details
Investments	BioPeak
Focus	Healthcare (owns Manipal Hospitals)
Stage	Seed to Series A
Signal	Hospital owner investing in longevity

Why it matters: Healthcare industry insider backing longevity clinics. Deep domain expertise.

Other Notable Angels

Angel	Background	Health Investments
Rohit MA	-	Eka Care
Kunal Shah	CRED founder	Health adjacent
Sanjeev Bikhchandani	Info Edge founder	Practo (early)

---

Strategic Investors

Corporate Health Bets

Corporate	Vehicle	Investments	Strategic Interest
Tata	Tata Digital	1MG acquisition	Digital health ecosystem
Reliance	Reliance Retail	Netmeds acquisition	E-pharmacy + health
Bajaj	Bajaj Finserv	Bajaj Finserv Health	Insurance + health services
Manipal	Claypond Capital	BioPeak	Hospital + longevity
Samsung	Partnership	Eka Care integration	Wearables + PHR

Pattern: Large corporates acquiring/partnering rather than building. Opportunity: AarogyaDost could be acquisition target or partner.

---

Global Investors in India Health

Investor	Portfolio	HQ	Notes
Tencent	Practo	China	Healthcare portfolio globally
General Catalyst	Function Health	USA	Longevity thesis
a16z	Neko Health	USA	Bio + health focus
Khosla Ventures	Various	USA	Health innovation

---

Funding by Category

Direct PHR

Company	Total Raised	Key Investors
Eka Care	$19.5M	Hummingbird (lead), 3one4, Mirae, Binny Bansal
DRiefcase	Bootstrapped	-
Health-e	Unknown	Government partnerships

Healthcare Platforms

Company	Total Raised	Key Investors
Practo	$228M	Peak XV, Tencent, Z47, AIA
MediBuddy	$125M+	Quadria, Lightrock
PharmEasy	$1.1B+	Prosus, TPG, Temasek

Longevity (Global)

Company	Total Raised	Key Investors
Neko Health	$260M	a16z, Lakestar
Function Health	$53M	General Catalyst
Prenuvo	$120M	-
BioPeak	Undisclosed	Nikhil Kamath, Ranjan Pai, Accel

E-Pharmacy

Company	Total Raised	Key Investors
Tata 1MG	$230M+	Tata (acquired)
Netmeds	$130M+	Reliance (acquired)

---

Investment Thesis Patterns

What's Getting Funded

Thesis	Evidence	AarogyaDost Fit
Longevity	BioPeak, Neko ($1.8B), $8.5B global	✅ Strong
AI in health	Eka Care AI, PharmEasy Swasth	✅ Strong
India-first	Eka Care, BioPeak	✅ Strong
Family/consumer	Eka Care positioning	✅ Strong
ABDM/digital health infra	Government push	✅ Strong

What's NOT Getting Funded

Anti-thesis	Reason	AarogyaDost Avoidance
Hospital EHR	Enterprise sales, slow	✅ Consumer focus
General wellness	Retention issues	✅ Records = permanent value
Insurance-first	Regulatory complexity	✅ Consumer-first

---

Funding Recommendations for AarogyaDost

Target Investors

Tier 1 Targets

Investor	Why	Approach
Accel	Prashanth Prakash longevity interest	Longevity + family angle
3one4	Eka Care investor, knows PHR	Differentiation from Eka
Hummingbird	Led Eka Care Series A	"Next evolution of PHR"

Angel Targets

Angel	Why	Approach
Nikhil Kamath	BioPeak investor, longevity focus	Data layer for longevity
Ranjan Pai	Healthcare domain, BioPeak	Hospital data aggregation

Strategic Targets

Corporate	Why	Approach
Samsung Health	Eka Care partner, wearables	Alternative PHR partner
Tata Health	1MG ecosystem	Data layer integration

Positioning for Fundraise

Narrative: "Longevity data hub for Indian families"

Key proof points:

1. Longevity sector = $8.5B, fastest growing

2. BioPeak generates 60GB data with no storage solution

3. Family-first = unique angle

4. ABDM-native = government tailwind

5. ₹999 pricing = mass market longevity

---

Related Documents

• [[README]] - Competitor hub

• [[strategic-insights]] - Market analysis

• [[06-longevity/_index]] - Longevity category deep dive

---

Last updated: 2025-11-21 Data sources: Tracxn, Crunchbase, news articles, company announcements